SRRK - Scholar Rock Is A Potential M&A Target Its Exploration of Obesity Market Garners Interest: Analyst | Benzinga
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to preserve muscle loss.
The analysis focuses on the potential of their lead program, apitegromab, for Spinal Muscular Atrophy (SMA), which is currently in a Phase 3 trial (SAPPHIRE) with data expected in Q4 2024.
Apitegromab benefits from robust Phase 2 data (TOPAZ) and shows promise as an add-on therapy to existing treatments for SMA.
The analyst commences coverage of Scholar Rock with a Strong Buy rating ...